Compare PPL & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PPL | WST |
|---|---|---|
| Founded | 1920 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3B | 23.9B |
| IPO Year | 2007 | 2004 |
| Metric | PPL | WST |
|---|---|---|
| Price | $31.97 | $370.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | $41.08 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 5.9M | 377.8K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.95% | 0.30% |
| EPS Growth | ★ 32.50 | 1.49 |
| EPS | 1.59 | ★ 4.07 |
| Revenue | ★ $9,042,000,000.00 | $2,886,900,000.00 |
| Revenue This Year | $7.23 | $6.76 |
| Revenue Next Year | $5.85 | $6.22 |
| P/E Ratio | ★ $20.11 | $91.79 |
| Revenue Growth | ★ 6.85 | 1.95 |
| 52 Week Low | $31.91 | $223.83 |
| 52 Week High | $40.11 | $386.00 |
| Indicator | PPL | WST |
|---|---|---|
| Relative Strength Index (RSI) | 23.92 | 63.12 |
| Support Level | N/A | $346.45 |
| Resistance Level | $36.80 | $386.00 |
| Average True Range (ATR) | 0.50 | 8.67 |
| MACD | -0.18 | 2.41 |
| Stochastic Oscillator | 11.43 | 75.37 |
PPL is a holding company of regulated utilities in Pennsylvania, Kentucky, and Rhode Island. The Pennsylvania regulated delivery and transmission segment distributes electricity to customers in central and eastern Pennsylvania. In Kentucky, LG&E and KU are involved in regulated electricity generation, transmission, and distribution. LG&E also provides regulated natural gas distribution. Rhode Island Energy operates electric and gas utilities in the state.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.